Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lung

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44365   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,710 result(s) found for: Lung. Displaying page 1 of 186.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005294-35 Sponsor Protocol Number: ELDERLY-NEXT Start Date*: 2009-02-26
    Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE
    Full Title: Multicenter Phase II study of Sequential Chemotherapy with Cisplatin/Gemcitabine Followed by Docetaxel in Elderly Advanced Non-Small-Cell Lung Cancer (NSCLC) patients
    Medical condition: elderly advanced NSCLC patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001160 LLT
    9.1 10001162 LLT
    9.1 10025031 LLT
    9.1 10001160 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012607-26 Sponsor Protocol Number: MIMEB Start Date*: 2009-12-10
    Sponsor Name:University of Cologne
    Full Title: MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Adv...
    Medical condition: Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC), first-line.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10025054 Lung cancer non-small cell stage IIIB LLT
    12.0 10025055 Lung cancer non-small cell stage IV LLT
    12.0 10029515 Non-small cell lung cancer recurrent PT
    12.0 10029521 Non-small cell lung cancer stage IIIB PT
    12.0 10029522 Non-small cell lung cancer stage IV PT
    12.0 10029521 Non-small cell lung cancer stage IIIB LLT
    12.0 10029522 Non-small cell lung cancer stage IV LLT
    12.0 10050017 Lung cancer metastatic LLT
    12.0 10059515 Non-small cell lung cancer metastatic LLT
    12.0 10061873 Non-small cell lung cancer LLT
    12.0 10066490 Progression of non-small cell lung cancer LLT
    12.0 10050017 Lung cancer metastatic PT
    12.0 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004771-22 Sponsor Protocol Number: Vs.12.11-07-2008 Start Date*: 2008-09-03
    Sponsor Name:Rigshospitalet, Kardiologisk afd
    Full Title: Prospective randomised dubbleblind placebocontrolled trial of calcium antagonist to prevent calcineurin induced nephropathy in lung transplanted patients
    Medical condition: kidney damage in ciclosporin treated lung transplant patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10029155 Nephropathy toxic PT
    14.1 10042613 - Surgical and medical procedures 10056409 Heart and lung transplant PT
    14.1 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005245-37 Sponsor Protocol Number: M06-880 Start Date*: 2008-04-17
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005729-25 Sponsor Protocol Number: LUNGVAC Start Date*: 2022-05-09
    Sponsor Name:Vestre Viken Health Trust
    Full Title: A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced ...
    Medical condition: Inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003790-18 Sponsor Protocol Number: N16HYP Start Date*: 2017-04-28
    Sponsor Name:The Netherlands Cancer Institute
    Full Title: Feasibility trial on combination of platinum doublets and hypofractionated radiotherapy for locally-advanced stage and / or inoperable non-small cell lung carcinoma
    Medical condition: Locally advanced non-small cell lung carcinoma stage III or inoperable stage II
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025051 Lung cancer non-small cell stage II LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001252 Adenosquamous cell lung cancer stage IIIA LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001253 Adenosquamous cell lung cancer stage IIIB LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025060 Lung cancer stage II LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025061 Lung cancer stage III LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001255 Adenosquamous cell lung cancer stage unspecified LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001246 Adenosquamous cell lung cancer NOS LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007696-16 Sponsor Protocol Number: TOGA 0601 Start Date*: 2008-06-02
    Sponsor Name:TOGA Thoracic Oncology Group Antwerp
    Full Title: Low molecular weight heparin in advanced non small cell lung cancer (NSCLC): a randomized open label phase III study evaluating the effect of enoxaparin (Clexane) on survival and symptom control in...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001005-85 Sponsor Protocol Number: ATX-NS-001 Start Date*: 2021-07-06
    Sponsor Name:Achilles Therapeutics UK Limited
    Full Title: An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer.
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001245 Adenosquamous cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001247 Adenosquamous cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001251 Adenosquamous cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001254 Adenosquamous cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023775 Large cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023779 Large cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023780 Large cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001246 Adenosquamous cell lung cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001253 Adenosquamous cell lung cancer stage IIIB LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023774 Large cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001252 Adenosquamous cell lung cancer stage IIIA LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025048 Lung cancer non-small cell recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069730 Large cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000570-22 Sponsor Protocol Number: 20060441 Start Date*: 2008-01-07
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Trial of AMG 745 or Placebo for the Treatment of Cachexia in Subjects with Non-Small Cell Lung Cancer
    Medical condition: Muscle cachexia due to non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064015 Cancer cachexia LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000130-11 Sponsor Protocol Number: EryDexFCTx1.0 Start Date*: 2011-07-25
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Clinical trials in rare diseases: therapeutic alternative to the use of oral corticosteroids in patients with cystic fibrosis underwent double lung transplantation.
    Medical condition: Double lung transplantation in patients with Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    14.1 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007107-32 Sponsor Protocol Number: M10-301 Start Date*: 2009-07-31
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-S...
    Medical condition: Non small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-005614-29 Sponsor Protocol Number: CC-486-NSCL-001 Start Date*: 2015-11-19
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembroliz...
    Medical condition: Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Completed) GR (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000659-23 Sponsor Protocol Number: 220365-2017 Start Date*: 2017-10-11
    Sponsor Name:Aarhus University Hospital
    Full Title: A Safety and feasibility study of standard dosing day 1 carboplatin AUC 5 every 3rd weeks with daily Navelbine® 20/30mg (oral) during 4 cycles (12 weeks) for the treatment of advanced NSCLC; A feas...
    Medical condition: Patients with metastatic or locally advanced Non-small-cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015855 10025044 Lung cancer LLT
    20.0 100000015841 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-003512-27 Sponsor Protocol Number: AIO-YMO/TRK-0120 Start Date*: 2021-12-08
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study
    Medical condition: Patients with EGFR-mutation positive NSCLC The target population will comprise 3 parallel cohorts, for each of which a minimum of 10 subjects is planned to be enrolled: 1. Irradiation of bone, sol...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025064 Lung carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007096 Cancer of lung LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002773-10 Sponsor Protocol Number: IRFMN-LUNG-8287 Start Date*: 2022-03-14
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A phase III prevention trial of canakinumab in subjects at high risk for lung cancer
    Medical condition: Subjects at high risk for lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058467 Lung neoplasm malignant PT
    20.0 100000004865 10078411 Primary prevention LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002539-25 Sponsor Protocol Number: ATOM 019 Start Date*: 2004-12-10
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI UDINE
    Full Title: Randomized phase II trial of second-line chemotherapy with oxaliplatin and docetaxel vs. docetaxel in patients with advanced non-small cell lung cancer (NSCLC)
    Medical condition: Second-line chemotherapy in advanced non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10059515 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018614-70 Sponsor Protocol Number: D791AC00014 Start Date*: 2010-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Gr...
    Medical condition: Non Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025053 Lung cancer non-small cell stage IIIA LLT
    12.1 10025054 Lung cancer non-small cell stage IIIB LLT
    12.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) NO (Completed) HU (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-002392-33 Sponsor Protocol Number: N12HYB Start Date*: 2012-06-12
    Sponsor Name:NKI-AVL
    Full Title: Phase I Hybrid study: combined stereotactic radiotherapy and conventional fractionation in stage II and III non small cell lung cancer with peripheral tumors smaller than 5 cm
    Medical condition: NSCLC stage III or inoperable stage II
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062041 Lung infiltration malignant PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023779 Large cell lung cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025036 Lung adenocarcinoma stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10025082 Lung disorder PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025031 Lung adenocarcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025069 Lung carcinoma cell type unspecified stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001250 Adenosquamous cell lung cancer stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025124 Lung squamous cell carcinoma stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025123 Lung squamous cell carcinoma stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025037 Lung adenocarcinoma stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005942-22 Sponsor Protocol Number: MK8669-021 Start Date*: 2009-01-15
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations.
    Medical condition: Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000541-38 Sponsor Protocol Number: CRAD001A2403 Start Date*: 2004-09-27
    Sponsor Name:NOVARTIS FARMA
    Full Title: A Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in addition to Certican 61668; and Steroids in de novo Heart Transplant Recipients.
    Medical condition: Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. It should be used in combination with ciclosporin for mic...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10056409 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Dec 07 13:54:59 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA